Identification of patients at high risk for recurrence in carcinoma of the ampulla of Vater: Analysis in 460 patients

Abstract

AimCarcinoma of the ampulla of Vater (CAV) shows a favorable prognosis compared to that with the other periampullary tumors, while some cases have a poor prognosis. The aims of the present study are to clarify the clinicopathological factors associated with poor recurrence‐free survival (RFS) in patients with CAV after curative resection and to validate the usefulness of adjuvant chemotherapy (AC).PatientsThe study design is a multicenter retrospective cohort study. Patients with CAV who underwent pancreaticoduodenectomy between January 2008 and December 2020 at 26 hospitals were analyzed. The 30 clinicopathological factors were evaluated. A propensity score matching (PSM) was used to compare between patients with and without AC.ResultsFinally, 460 patients were analyzed. Median duration of follow‐up was 47.2 months. Twenty‐one prognostic factors associated with poor RFS were identified by univariate analysis. In multivariate analysis, aged ≥71, tumor diameter ≥12 mm, pT2 or higher stage (pT≥2), portal vein invasion (PV+), venous invasion(V+), and node positive disease (pN+) were independent prognostic factors for poor RFS. Out of 80 patients who received AC, 63 patients were assigned to analysis for PSM. The results showed no beneficial effect of AC on RFS. The preoperative factors potentially predicting pT≥2, V+, and/or N+ were at least one of following; (1) CA19‐9 > 37 IU/mL, (2) ulcerative or mixed type appearance, (3) except for well‐differentiated tumor, or (4) except for intestinal subtype of histology.ConclusionsAged ≥71, tumor diameter ≥12 mm, pT≥2, PV+, V+, and pN+ were independent prognostic factors for poor RFS in patients with CAV. An additional therapeutic strategy may be desirable in CAV patients at high risk for recurrence.

Preliminary response to Tislelizumab plus chemotherapy drugs in patient with periampullary carcinoma: a report of one case and a literature review

“…Currently, surgical resection remains the main therapy option to improve long-term survival and is practicable in approximately 50% of ampullary cancer cases ( 2 ). Nonetheless, the overall survival time is still limited due to the high risk of recurrence and metastasis ( 3 ). Therefore, adjuvant therapy (AT), such as chemotherapy, is recommended for improving the long-term survival ( 4 ).…”